Nurexone Biologic Stock Today
| NRX Stock | 0.74 0.01 1.33% |
PerformanceInsignificant
| Odds Of DistressQuite High
|
NurExone Biologic is selling for under 0.74 as of the 20th of March 2025; that is 1.33% down since the beginning of the trading day. The stock's lowest day price was 0.74. NurExone Biologic has more than 65 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Moving against NurExone Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
NurExone Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. NurExone Biologic's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding NurExone Biologic or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
NurExone Biologic (NRX) is traded on TSX Venture Exchange in Canada and employs 15 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 52.46 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate NurExone Biologic's market, we take the total number of its shares issued and multiply it by NurExone Biologic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. NurExone Biologic classifies itself under Biotechnology sector and is part of Health Care industry. The entity has 70.89 M outstanding shares of which 2.31 K shares are now shorted by private and institutional investors with about 0.1 days to cover all short positions.
NurExone Biologic generates negative cash flow from operations
Check NurExone Biologic Probability Of Bankruptcy
Ownership AllocationNurExone Biologic maintains a total of 70.89 Million outstanding shares. NurExone Biologic secures 4.51 % of its outstanding shares held by insiders and 0.0 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check NurExone Ownership Details
NurExone Biologic Risk Profiles
Although NurExone Biologic's alpha and beta are two of the key measurements used to evaluate NurExone Biologic's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.73 | |||
| Semi Deviation | 4.41 | |||
| Standard Deviation | 5.01 | |||
| Variance | 25.14 |
NurExone Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in NurExone Biologic without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
NurExone Biologic Corporate Management
Elected by the shareholders, the NurExone Biologic's board of directors comprises two types of representatives: NurExone Biologic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NurExone. The board's role is to monitor NurExone Biologic's management team and ensure that shareholders' interests are well served. NurExone Biologic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NurExone Biologic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nirit DroriCarmi | Head Development | Profile | |
| Nirit MSc | Head Development | Profile | |
| Limor Chen | Head Partnerships | Profile | |
| Pr MD | Head Board | Profile |
Additional Tools for NurExone Stock Analysis
When running NurExone Biologic's price analysis, check to measure NurExone Biologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NurExone Biologic is operating at the current time. Most of NurExone Biologic's value examination focuses on studying past and present price action to predict the probability of NurExone Biologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NurExone Biologic's price. Additionally, you may evaluate how the addition of NurExone Biologic to your portfolios can decrease your overall portfolio volatility.